Entera Bio (ENTX) Competitors

Entera Bio (NASDAQ:ENTX) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Do institutionals and insiders have more ownership in ENTX or ARCT?

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by company insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has stronger valuation and earnings, ENTX or ARCT?

Entera Bio has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$180K	506.32	-$9.54M	-$0.26	-7.68
Arcturus Therapeutics	$109.80M	4.51	-$80.94M	-$2.23	-8.17

Does the media favor ENTX or ARCT?

In the previous week, Arcturus Therapeutics had 20 more articles in the media than Entera Bio. MarketBeat recorded 34 mentions for Arcturus Therapeutics and 14 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.82 beat Arcturus Therapeutics' score of 0.55 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Arcturus Therapeutics	4 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ENTX or ARCT?

Entera Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500.

Do analysts rate ENTX or ARCT?

Entera Bio presently has a consensus price target of $10.00, suggesting a potential upside of 401.00%. Arcturus Therapeutics has a consensus price target of $50.00, suggesting a potential upside of 174.35%. Given Entera Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Entera Bio is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Arcturus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ENTX or ARCT more profitable?

Arcturus Therapeutics has a net margin of -49.26% compared to Entera Bio's net margin of -4,525.11%. Arcturus Therapeutics' return on equity of -24.87% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	-4,525.11%	-77.75%	-68.13%
Arcturus Therapeutics	-49.26%	-24.87%	-17.75%

Summary

Arcturus Therapeutics beats Entera Bio on 9 of the 17 factors compared between the two stocks.